146 related articles for article (PubMed ID: 377968)
21. A new ultra-low-dose combination oral contraceptive.
Woutersz TB
J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
[TBL] [Abstract][Full Text] [Related]
22. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
23. Clinical experience with a low-dose contraceptive agent. European studies.
Haspels AA
J Reprod Med; 1983 Jan; 28(1 Suppl):71-6. PubMed ID: 6403703
[TBL] [Abstract][Full Text] [Related]
24. [Use of Ovidon, Rigevidon and Postinor for contraception].
Kulakov VI; Barinov AM; Prilepskaia VN
Akush Ginekol (Mosk); 1983 Nov; (11):22-4. PubMed ID: 6666791
[No Abstract] [Full Text] [Related]
25. A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.
Xu Y; Gabriel K; Wang Y; Zhou Y; Eisele O; Vutikullird A; Mikol DD; Lee E
CNS Drugs; 2019 May; 33(5):513-522. PubMed ID: 30963506
[TBL] [Abstract][Full Text] [Related]
26. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
[TBL] [Abstract][Full Text] [Related]
27. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
28. A randomized double-blind trial of two low dose combined oral contraceptives.
Bounds W; Vessey M; Wiggins P
Br J Obstet Gynaecol; 1979 Apr; 86(4):325-9. PubMed ID: 373792
[TBL] [Abstract][Full Text] [Related]
29. [Combined hormonal contraception in cycles artificially extended].
Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
[TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy, acceptability and metabolic effects of new low dose combined oral contraceptives.
Bergstein NA
Acta Obstet Gynecol Scand Suppl; 1976; 54():51-9. PubMed ID: 788446
[No Abstract] [Full Text] [Related]
31. Development of the ratio of levonorgestrel, 0.15 mg, to ethinyl estradiol, 0.03 mg.
Christie T
J Reprod Med; 1983 Jan; 28(1 Suppl):63-5. PubMed ID: 6403701
[No Abstract] [Full Text] [Related]
32. [Clinical study of a triphasic contraceptive preparation (Norgestimate 180/215/250 micrograms + ethinylestradiol 35 micrograms) in a population of Czech women].
Paseka J; Unzeitig V; Horejsí J; Rotta L; Chroust K; Cibula D
Ceska Gynekol; 1999 Jul; 64(4):246-54. PubMed ID: 10568064
[TBL] [Abstract][Full Text] [Related]
33. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney BP; Mathias A
Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
[TBL] [Abstract][Full Text] [Related]
34. Less estrogen in new oral contraceptive.
Am J Nurs; 2003 Apr; 103(4):111-2. PubMed ID: 12677126
[No Abstract] [Full Text] [Related]
35. [Clinical use of combined contraceptive preparations of Hungarian manufacture].
Farkas M
Akush Ginekol (Mosk); 1983 Nov; (11):11-4. PubMed ID: 6364870
[TBL] [Abstract][Full Text] [Related]
36. Contraception with levonorgestrel, 0.15 mg, and ethinyl estradiol, 0.03 mg. Clinical studies in Latin America.
Moggia AV
J Reprod Med; 1983 Jan; 28(1 Suppl):77-80. PubMed ID: 6403704
[TBL] [Abstract][Full Text] [Related]
37. Preliminary results from a swedish multicenter trial of a new low dose combined oral contraceptive.
Ingemanson CA; Jägerhorn M; Zizala J; Nilsson B; Zador G
Acta Obstet Gynecol Scand Suppl; 1976; 54():71-5. PubMed ID: 788449
[TBL] [Abstract][Full Text] [Related]
38. [A continuous experience of the use of norethindrone-ethinyl estradiol combination in small doses as a contraceptive].
Ruíz Moreno JA; Rubio Lotvin B; Bolio Arista R; de Larios NM
Ginecol Obstet Mex; 1977 Feb; 41(244):179-84. PubMed ID: 321297
[TBL] [Abstract][Full Text] [Related]
39. The 150/30 formulation. Experience in the United Kingdom.
Guillebaud J
J Reprod Med; 1983 Jan; 28(1 Suppl):66-70. PubMed ID: 6403702
[TBL] [Abstract][Full Text] [Related]
40. Rationale for new oral contraceptive dosing.
Williams JK
Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
